{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:11:09Z","timestamp":1791670269189,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Research interest in Hidradenitis Suppurativa (HS) has grown exponentially over the past decades. Several groups have worked to develop novel scores that address the drawbacks of existing investigator\u2010assessed and patient\u2010reported outcome measures currently used in HS trials, clinical practice and research. In clinical trial settings, the drawbacks of the HiSCR have become apparent; mainly, it is lack of a dynamic measurement of draining tunnels. The newly developed (dichotomous) IHS4 and HASI\u2010R are backed up by adequate validation data and are good contenders to become the new primary outcome measure in HS clinical trials. Patient\u2010reported outcomes, as well as physician reported measures, are being developed by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). For example, the Hidradenitis Suppurativa Quality of Life (HiSQOL) score is a validated measure of HS\u2010specific quality of life and is already being used in many HS trials. Magnitude of pain measurement via a 0\u201310 numerical rating scale is well\u2010established; however, consensus is still required to ensure consistent administration and interpretation of the instrument. A longitudinal measurement over multiple days rather than at one time point, such as for example the Pain Index could provide increased reliability and reduced recall bias. Ultimately, these newly developed scores and tools can be included in a standardized registry to be used in routine clinical practice.<\/jats:p>","DOI":"10.1111\/exd.14609","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T07:23:12Z","timestamp":1652858592000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["New treatments and new assessment instruments for Hidradenitis suppurativa"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-3814","authenticated-orcid":false,"given":"Kelsey R.","family":"van Straalen","sequence":"first","affiliation":[{"name":"Department of Dermatology University of Michigan  Ann Arbor Michigan USA"},{"name":"European Hidradenitis Suppurativa Foundation e.V.  Dessau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V.  Dessau Germany"},{"name":"Department of Dermatology, Division of Infection &amp; Immunity Cardiff University  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V.  Dessau Germany"},{"name":"Institute for Health Care Services Research in Dermatology and Nursing University Hospital Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2608","authenticated-orcid":false,"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V.  Dessau Germany"},{"name":"Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg  Dessau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14475"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18244"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18335"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19565"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270"},{"key":"e_1_2_11_9_1","unstructured":"07\u20102019\u2010InflaRx reports additional analysis of the SHINE phase IIb results for IFX\u20101 in hidradenitis suppurativa: InflaRx;2019. [updated 18 July 2019]. Available from:https:\/\/www.inflarx.de\/Home\/Investors\/Press\u2010Releases\/07\u20102019\u2010InflaRx\u2010Reports\u2010Additional\u2010Analysis\u2010of\u2010the\u2010SHINE\u2010Phase\u2010IIb\u2010Results\u2010for\u2010IFX\u20101\u2010in\u2010Hidradenitis\u2010Suppurativa\u2010.html. Accessed March 20 2022."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2905"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17598"},{"key":"e_1_2_11_12_1","article-title":"Development and validation of an IHS4 dichotomous outcome to assess treatment effect","author":"Tzellos T","year":"2022","journal-title":"Exp Dermatol"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.089"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17716"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16672"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.3655"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014733"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16093"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18692"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19344"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-2-277"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7212.731"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2005.06.010"},{"key":"e_1_2_11_24_1","first-page":"1643","article-title":"Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient\u2010Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa","volume":"33","author":"Chernyshov PV","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.18.06021-2"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17306"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.021"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15233"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2017.016"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2815"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3269050156","article-title":"Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage","volume":"26","author":"McKenzie SA","year":"2020","journal-title":"Dermatol Online J"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191940"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0225"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9124046"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.016"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19798"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503606"},{"key":"e_1_2_11_39_1","unstructured":"01\u20102022\u2010InflaRx initiates phase III clinical program with vilobelimab in hidradenitis suppurativa: InflaRx;2022[updated 5 January 2022. Available from:https:\/\/www.inflarx.de\/Home\/Investors\/Press\u2010Releases\/01\u20102022\u2010InflaRx\u2010Initiates\u2010Phase\u2010III\u2010Clinical\u2010Program\u2010with\u2010Vilobelimab\u2010in\u2010Hidradenitis\u2010Suppurativa.html. Accessed March 20 2022."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16520"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21247"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14609","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/exd.14609","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T21:11:26Z","timestamp":1692738686000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.14609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":40,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/exd.14609"],"URL":"https:\/\/doi.org\/10.1111\/exd.14609","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"2022-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}